Risk factor
Strong & resilient to price shocks
Profitability factor
Excellent growth
About
Ipca Laboratories Limited is a pharmaceutical company that manufactures and distributes a comprehensive range of finished drug products (formulations) and essential raw materials, known as Active Pharmaceutical Ingredients (APIs). Its API portfolio supports treatments for conditions such as hypertension, malaria, parasitic infections, and also includes diuretics and disease-modifying anti-rheumatic drugs (DMARDs). The company provides an extensive selection of generic and branded formulations across numerous therapeutic segments. These encompass cardiovascular health, diabetes management, neurological disorders, gastroenterology, and dermatology. Furthermore, Ipca's product lines address oncology, rheumatology, respiratory conditions, ophthalmology, urology, mental health, infectious diseases, pain management, allergies, nutritional support, and various other specialized medical requirements. Primarily operating in India, Ipca Laboratories also boasts a significant international footprint, exporting its products to approximately 100 countries worldwide. The company, which has its headquarters in Mumbai, India, was established in 1949.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair value on
Target Price
The average target price of IPCALAB.NS is 1601 and suggests 2% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation t